STAG2 mutations and 3D genome organization in glioblastoma
Official title: STAG2 mutations and 3D genome organization in glioblastoma multiforme
Funded at Georgetown University · NIH-11353893 · Data updated 2026-11-12
A study in adults with glioblastoma examines how STAG2 gene mutations may change the 3D structure of DNA in tumor cells and drive cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | August 10, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $535,445 |
| NIH project number | 5R01CA267872-05 |
| Project ID | NIH-11353893 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma, or readily available GBM tumor samples/cell models derived from those patients.
✕Less likely to help
Patients without GBM or without access to relevant tumor samples may not benefit.
What this research studies
This project will look at how changes in the STAG2 gene affect the 3D folding of the genome in glioblastoma cells and how that might turn on or off genes involved in cancer. Researchers will use advanced genome mapping and RNA analysis to compare tumor cells with and without STAG2 mutations, building on new bioinformatics tools to identify meaningful genome loops. The goal is to understand a key mechanism of GBM biology that could reveal new avenues for therapy. Participation would involve laboratory analyses using human tumor samples or cell models generated from them.
Why it matters
Potential benefit: Understanding STAG2-driven changes could lead to new targets or strategies for treating glioblastoma.
How similar studies have gone: Preliminary work in this area uses Hi-C and RNA-seq to link genome structure with gene expression in GBM, showing promise for identifying actionable mechanisms.
Where this research is happening
-
Georgetown University
Washington, United States Active
Researchers
- Principal investigator: Waldman, Todd a — Georgetown University
- Study coordinator: Waldman, Todd a
Related research
Other NIH-funded projects on the same topics.
-
Role of a brain tumor RNA in glioblastoma where a unique lncRNA may drive cancer cells
A small, focused NIH grant explores how a brain cancer–related RNA called LINC01896 might control the growth of glioblastoma stem cells and influence treatment resistance.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Enhanced delivery of neural stem cells to brain cancer with a biodegradable gel and focused ultrasound
A new treatment approach uses patient-friendly neural stem cells delivered over several months with a biodegradable gel and ultrasound to target glioblastoma.
-
Long-lasting stem-cell delivery for glioblastoma using an injectable gel and focused ultrasound
An injectable, biodegradable gel that slowly releases tumor‑killing neural stem cells, paired with focused ultrasound to allow non-surgical re-dosing, for people with glioblastoma.
-
Understanding the STAG2 Gene in Brain Tumors
This project aims to understand how changes in a specific gene called STAG2 contribute to the growth of glioblastoma, a common type of brain tumor.
-
Understanding how metabolic changes help glioblastoma resist radiation treatment
This study is looking at how glioblastoma, a tough type of brain cancer, manages to survive radiation therapy, and it hopes to find new ways to make this treatment work better for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.